Nanoparticle vaccines to boost the immune attack on melanoma
Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids
A nanoparticle vaccine designed to help people with advanced melanoma by teaching the immune system to better spot and destroy melanoma cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11294305 on NIH RePORTER |
What this research studies
This project develops vaccines from tiny spherical nanoparticles (spherical nucleic acids, SNAs) that carry immune-stimulating DNA and short pieces of melanoma protein. Because of their 3D shape, these particles present several melanoma targets at once so the immune system has a better chance to recognize cancer cells and not be tricked. Similar SNA designs have produced strong anti-tumor responses in lab and animal tests, and a related SNA adjuvant is already in an early Phase 1b/2 clinical trial. If successful, these vaccines could move toward testing in people with advanced or high‑risk melanoma.
Who could benefit from this research
Good fit: People with advanced or high‑risk melanoma, especially those whose tumors resist current treatments, would be the main candidates for future testing.
Not a fit: People without melanoma, those with other cancer types, or patients with severe immune suppression or contraindications to vaccination are unlikely to benefit from this vaccine approach.
Why it matters
Potential benefit: If successful, this approach could produce vaccines that reduce melanoma recurrence and strengthen immune control of tumors.
How similar studies have performed: Related SNA adjuvants have shown enhanced immune responses in preclinical studies and are being tested in a Phase 1b/2 trial, while multi‑antigen SNA vaccines remain a newer strategy.
Where this research is happening
Chicago, UNITED STATES
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Mirkin, Chad a. — Northwestern University
- Study coordinator: Mirkin, Chad a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.